Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum
Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact. Read More
CARsgen advances CAR T-cell therapies with breakthrough designation for satri-cel and first dose of KJ-C2219
CARsgen Therapeutics Holdings Limited has taken significant strides in the field of CAR T-cell therapy with two major developments in its pipeline. The company’s lead ... Read More
Akeso’s Gumokimab poised to redefine Psoriasis treatment
Akeso, Inc., a leading biopharmaceutical innovator based in Hong Kong, is making significant strides in the treatment of autoimmune diseases. The company recently announced that ... Read More
Keymed Biosciences secures NMPA approval for Stapokibart in chronic rhinosinusitis treatment
Keymed Biosciences Inc. (HKEX: 02162) has received a significant regulatory endorsement as the National Medical Products Administration (NMPA) of China approved its supplemental New Drug ... Read More
Sanofi strengthens cardiovascular portfolio with Aficamten rights in Greater China
Cytokinetics, Incorporated (NASDAQ: CYTK) saw its shares climb by 4.8% after announcing a landmark agreement with Sanofi (NASDAQ: SNY). The deal grants Sanofi exclusive rights ... Read More
Akeso Biopharma raises $250m to accelerate international clinical trials
Akeso Biopharma has successfully raised approximately $250 million through a share placement, drawing significant recognition from international investment firms. The placement saw a majority of ... Read More
Summit Therapeutics set to begin HARMONi trial of Ivonescimab in EGFR-mutant lung cancer
Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the HARMONi Phase III clinical trial. This pivotal ... Read More
China’s NMPA expands AstraZeneca’s Forxiga use as heart failure treatment
China's National Medical Products Administration (NMPA) has approved AstraZeneca's Forxiga (dapagliflozin) for diminishing the risk of cardiovascular fatalities and hospitalizations in adults diagnosed with symptomatic ... Read More
AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More
Gufic Biosciences secures NMPA approval to market Prilocaine (API) in China
Gufic Biosciences has received approval from the National Medical Products Administration (NMPA) in China for its product, Prilocaine (API), an amide-type local anesthetic. The approval ... Read More